Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

Peter W. Szlosarek(St Bartholomew's Hospital), Michael Sheaff(Royal London Hospital)

JTO Clinical and Research Reports

September 3, 2020

10.1016/j.jtocrr.2020.100093

Cited by 30

Related Papers

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

|Cell Death and Disease|2012|151

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma

|Pharmacological Reports|2023|5